Atlas Trials

A Triple-targeted Cell Preparation Targeting CD19/CD20/CD22 in Patients With Relapsed/Refractory B-cell Acute Lymphocytic Leukemia

Clinical trial NCT05292898 · TERMINATED

Trial details

NCT number
NCT05292898
Sponsor
Institute of Hematology & Blood Diseases Hospital, China
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Acute Lymphocytic Leukemia
Start date
2022-03-14
Primary completion
2025-01-10
Enrollment
10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.